Prinoxodan manufacturers
- Prinoxodan
-
- $793.00
-
2026-05-11
- CAS:111786-07-3
- Purity: 98.99%
- Supply Ability: 10g
|
| | Prinoxodan Basic information |
| Product Name: | Prinoxodan | | Synonyms: | Prinoxodan;RGW2938;Prinoxodan (RGW2938);2(1H)-Quinazolinone, 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-;3-Methyl-6-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-3,4-dihydroquinazolin-2(1H)-one | | CAS: | 111786-07-3 | | MF: | C13H14N4O2 | | MW: | 258.28 | | EINECS: | | | Product Categories: | | | Mol File: | 111786-07-3.mol |  |
| | Prinoxodan Chemical Properties |
| Melting point | >250 °C | | density | 1.47±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 13.58±0.40(Predicted) | | color | White to yellow |
| | Prinoxodan Usage And Synthesis |
| Uses | Cardiotonic. | | in vivo | Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR[2]. |
| | Prinoxodan Preparation Products And Raw materials |
|